Despite House Vote, IPAB Lives
Thursday's House vote to eliminate the Independent Payment Advisory Board, or IPAB as it is commonly known, provides Republicans and some Democrats with symbolic bragging rights and not much more. There's very little likelihood that the Democrat-controlled Senate, which is home to some of IPAB's biggest boosters, will even take up the issue during this legislative session.
That means IPAB, which is part of the massive Patient Protection and Affordable Care Act, remains the law of land…for now.
IPAB is the cost-cutting board empowered by PPACA to analyze the drivers of Medicare cost growth and recommend policies to control that growth.
IPAB membership
The President, in concert with Congressional leaders, will appoint 15 individual IPAB members who must be confirmed by the Senate. IPAB members will serve six years and make about $165,000 annually. The legislation mentions expertise in things like health finance and economics, actuarial science, and health facility management. Among the membership requirements: employers, physicians, consumers, and experts in prescription drug benefits.
It will be a full-time job, with members expected to keep up with healthcare cost trends, utilization numbers, patient access to care, and quality issues so they can step in when needed to make proposals to rein in Medicare cost.
- $6.4B Henry Ford, Beaumont Merger Failed on Cultural Hurdles
- Don't Let Nurses Sink Your Bottom Line
- Fortunately, Angelina Jolie Isn't On Medicare
- Hospitals Profit On Bloodstream Infections
- Less Blood Testing for Some Surgeries Safe, Cost Effective
- How Chargemaster Data May Affect Hospital Revenue
- House Lawmakers Grill CMS Over Health Exchange Navigators
- Primary Care Docs Average More Hospital Revenue Than Specialists
- Lower ED Margins Demand a Better Strategy
- ED Physicians Key to Half of Hospital Admissions

Comments are moderated. Please be patient.
Tyco Branh (3/23/2012 at 12:10 PM)
IPAB is one of the strongest ways we can try to bring down costs and increase quality. Without the pressure of special interest groups, these members can look at the science and decide objectively. Of course groups like doctors and pharma companies, afraid of how the decisions will hurt the bottom line, hate this idea.